Phillip P. Chan - Dec 6, 2022 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Executive Officer, Director
Signature
/s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan
Stock symbol
CTSO
Transactions as of
Dec 6, 2022
Transactions value $
$30,475
Form type
4
Date filed
12/8/2022, 03:30 PM
Previous filing
Sep 12, 2022
Next filing
Dec 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Purchase $18.1K +14.3K +1.65% $1.26 882K Dec 6, 2022 Direct F1
transaction CTSO Common Stock Purchase $12.4K +9.85K +1.12% $1.26 891K Dec 7, 2022 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 reflect open market purchases made by the reporting person.
F2 Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
F3 (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and
F4 (continued from footnote 3) (c) 598,753 shares of the Issuer's common stock owned by the reporting person, inclusive of the total of 24,141 shares of the Issuer's common stock reported on this Form 4.